Newest evidence for tetrahydrocannabinol: cannabidiol oromucosal spray from randomized clinical trials
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F19%3AN0000068" target="_blank" >RIV/00064190:_____/19:N0000068 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11120/19:43917584
Result on the web
<a href="http://dx.doi.org/10.2217/nmt-2018-0050" target="_blank" >http://dx.doi.org/10.2217/nmt-2018-0050</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.2217/nmt-2018-0050" target="_blank" >10.2217/nmt-2018-0050</a>
Alternative languages
Result language
angličtina
Original language name
Newest evidence for tetrahydrocannabinol: cannabidiol oromucosal spray from randomized clinical trials
Original language description
Subsequent to EMA approval of tetrahydrocannabinol (THC): cannabidiol (CBD) oromucosal spray based on results of various studies, including an enriched-design clinical trial, two newer postapproval randomized trials have confirmed its efficacy and safety for treating resistant multiple sclerosis spasticity, while simultaneously addressing specific authoritie's concerns. A double-blind, placebo-controlled, Phase IV trial, conducted as part of the EMA's risk management plan, found no effect of THC:CBD spray on cognition and mood after 50 weeks of treatment. In the Sativex (R) as add-on therapy versus further optimized first-line ANTispastics (SAVANT) study, add-on THC:CBD spray was significantly more effective than readjusting standard antispasticity therapy and provided new evidence of efficacy as requested by German authorities. SAVANT results support practical recommendations for treating resistant multiple sclerosis spasticity in daily practice.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30103 - Neurosciences (including psychophysiology)
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
NEURODEGENERATIVE DISEASE MANAGEMENT
ISSN
1758-2024
e-ISSN
1758-2032
Volume of the periodical
9
Issue of the periodical within the volume
5, Supplement: S
Country of publishing house
GB - UNITED KINGDOM
Number of pages
5
Pages from-to
9-13
UT code for WoS article
000458334300003
EID of the result in the Scopus database
2-s2.0-85060921291